Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA tattoo vaccination with sig-HELP-E6SH/E7SH-kdel in HPV16-positive vulvar intraepithelial neoplasia
NL-OMON47893Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2016
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sig-HELP-E6SH/E7SH-kdel DNA vaccine in vulvar intraepithelial neoplasia (VIN), sponsored by Netherlands Cancer Institute. Primary endpoint: Systemic HPV-specific immune response. Started Dec 2016; status: active, not recruiting.
02
Drugs
sig-HELP-E6SH/E7SH-kdel DNA vaccine
03
Conditions
vulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on NL-OMON47893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47893.